ArticleParasites & vectors2025
A nucleoside transporter on the mitochondria of T. gondii is essential for maintaining normal growth of the parasite.
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Identification of TgENT1 as the TgUUT1 Uracil/Uridine Transporter ofPathogens (Basel, Switzerland) · 2026Article
- Transporters, an important but poorly studied area of Toxoplasma gondii.Parasites & vectors · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundToxoplasma gondii invades almost all nucleated cells of warm-blooded animals, but T. gondii lacks the ability to synthesize purines; therefore, it must scavenge purines from host cells to fuel its proliferation and propagation. Through exogenous expression, the adenosine transporter TgAT1 has been validated for its ability to transport both oxypurine nucleosides and nucleobases across the parasite plasma membrane, although its affinity for the substrate is low. Further studies have shown that T. gondii also has a high-affinity purine and pyrimidine nucleoside transport system (TgAT2), but this protein has not been identified thus far.
methodsHere, we identified three novel nucleoside transporters in T. gondii by homology alignment. Using immunofluorescence staining, we found that TgNT1, TgNT2, and TgNT3 are localized to the mitochondria, plasma membrane, and endoplasmic reticulum (ER), respectively. We also performed conditional knockout of TgNT1 and direct knockout of TgNT2/TgNT3 using CRISPR/Cas9 technology.
resultsTgNT1 is crucial for the in vitro growth and proliferation of T. gondii, whereas the other two genes are dispensable. Conditional depletion of TgNT1 impairs multiple metabolic pathways in both the mitochondria and cells of the parasite, with the most significant changes manifesting in the levels of various nucleosides. Carbon metabolism is also affected, as evidenced by alterations in metabolite levels within both the electron transport chain and the tricarboxylic acid cycle. The impairment of adhesion and invasion functions appears to be strongly associated with a reduction in the content of the initial lipid involved in glycosylphosphatidylinositol (GPI)-anchored lipid modification, which may underlie the inhibition of T. gondii's invasive capacity. Notably, TgNT1 is the first nucleoside transporter protein that is localized in the mitochondria of T. gondii. Given that TgNT1 has no homologous proteins in mammals, it holds promise as a potential drug target.
conclusionsTgNT1, a nucleoside transporter located in the mitochondria of T. gondii, is essential for maintaining the normal growth of the parasite.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.